Clinical trial NCT05512429: Prognostic Value of Body Composition in Lung Cancer
Official title: Prognostic Value of Body Composition in Therapy-Naïve Patients With Non-Small Cell Lung Cancer
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Body Composition and Non-small Cell Lung Cancer
Lead sponsor: Marmara University
Sponsor class: OTHER
First posted: 2022-08-23
Enrollment: 83
Sex: ALL
Minimum age (years): 18
Maximum age (years): 80
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: COHORT
Time perspective: RETROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Eighty-three patients with stage-IV NSCLC who received at least one cycle of platinum based chemotherapy (PBCT) or tyrosine kinase inhibitor (TKI) therapy and who underwent pre treatment FDG PET/CT from June 2012 to February 2019

Brief summary: The effect of body composition on the survival rate is one of the research topics of interest in cancer patients and gaining attention in the last years. Body mass index is often used a proxy measure of total adiposity and previous studies examining the relationship between BMI and cancer outcomes have been showed distinct results . Obese patients with malignancies such as colorectal, breast, and pancreatic cancers, have been shown to have a worse prognosis than normal-weight patients . Nevertheless, obese patients with non small cell lung cancer(NSCLC) have been observed to have a better clinical outcome than normal/low-weight cancer patients . In this study, we examined the effects of subcutaneous adipose tissue, visceral adipose tissue and skeletal muscle volumes on survival in metastatic NSCLC patients under different treatment regimens. Since there is no standard method for adipose tissue measurement, we evaluated the abdominal cavity with multi-slice and single-slice computed tomography measurements.


Eligibility criteria: Inclusion Criteria:

1. Having a pathological diagnosis of non small cell lung cancer
2. Having a stage-IV disease
3. To have received at least one course of treatment
4. Presence of positron emission tomography /computed tomography (PET/CT) examination before treatment and having it taken in our hospital
5. The data about the study can be accessed in our center.
6. To be over 18 years old

Exclusion Criteria:

1. Unable to access patients data
2. PET/CT CDs cannot be accessed or are not suitable for evaluation.

Primary outcomes:
measure: To evaluate the impact of visceral adipose tissue (VAT) on the prognosis of metastatic non-small cell lung cancer (NSCLC) patients.
timeFrame: through study completion, an average of 6 months
measure: To evaluate the impact of subcutaneous adipose tissue (SAT) on the prognosis of metastatic non-small cell lung cancer (NSCLC) patients.
timeFrame: through study completion, an average of 6 months
measure: To evaluate the impact of skeletal muscle mass volume (SMMV) on the prognosis of metastatic non-small cell lung cancer (NSCLC) patients.
timeFrame: through study completion, an average of 6 months
Secondary outcomes:
Other outcomes:
Locations:
city: İstanbul
country: Turkey
facility: Tuğba Kıratlı Yolcu
Study officials:
References: